UPMC Hillman Cancer Center

In an interview for Cervical Cancer Awareness Month, Robert P. Edwards, MD, discussed the current treatment landscape of cervical cancer as well as future prospects.

Liza C. Villaruz, MD, discusses what research in the KRAS G12C-mutated non–small cell lung cancer space has appeared to be most promising in recent years.

In an interview with Targeted Oncology, Liza C. Villaruz, MD, discussed important new therapies for biomarker-driven NSCLC, and novel biomarkers that may bring new treatments in the near future.

Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.

With a plethora of chemotherapy agents currently unavailable for patients with solid tumors and hematologic malignancies, experts are calling for the FDA and pharmaceutical companies to make important changes.

Adam Brufsky, MD, PhD, FACP, discusses the real-world efficacy of letrozole in combination with palbociclib as treatment of patients with estrogen receptor-positive, HER2-negative, advanced breast cancer, based on race and ethnicity.